Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics

por Gao, Yang, Kabotyanski, Elena B., Shepherd, Jonathan H., Villegas, Elizabeth, Acosta, Deanna, Hamor, Clark, Sun, Tingting, Montmeyor-Garcia, Celina, He, Xiaping, Dobrolecki, Lacey E., Westbrook, Thomas F., Lewis, Michael T., Hilsenbeck, Susan G., Zhang, Xiang H.-F., Perou, Charles M., Rosen, Jeffrey M.
Publicado 2021